Neurocrine Biosciences (NBIX) stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.
Despite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.
However, the company's guidance for 2025 fell short of expectations, projecting full-year net product sales between $2.5 billion and $2.6 billion. Investors viewed this outlook as conservative, leading to the stock's sharp decline. NBIX's CEO Kyle Gano remained optimistic, stating, "With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.